Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of RN-1101 in patients with solid tumors
jRCT2031220477Phase 1Suspended
- Sponsor
- RIN Institute
- Start
- Jan 2023
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of RN1101 in Nonhematologic neoplasms and colorectal cancer (CRC) (3 cohorts), sponsored by RIN Institute. Primary endpoint: Dose-limiting toxicity (DLT). Started Jan 2023; status: suspended.
02
Drugs
RN1101
03
Conditions
Nonhematologic neoplasmscolorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2031220477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220477.